Metformin in Breast Cancer, Visualized With Positron Emission Tomography

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general purpose of the trial is to investigate whether metformin is taken up into the breast tumor. Studies in the last few years have shown an effect of metformin on cell proliferation on breast cancer. It is though unclear whether the effect on tumor is direct, indirect or a combination of the two. The investigators plan to:

* investigate if metformin is taken up in breast cancer using our novel 11C-metformin tracer and positron emission tomography (PET)
* investigate whether the uptake is correlated to the amounts of organic cation transporters (OCT1-3, MATE 1 \&2 and PMAT) using quantitive polymerase chain reaction (qPCR).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32

NCT01666171

Breast Cancer

UNKNOWN

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

NCT02028221

Breast Cancer Prevention

COMPLETED PHASE2

The Effect of Metformin on Breast Cancer Patients

NCT04559308

Breast Cancer

UNKNOWN PHASE2

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

NCT01286233

Breast Cancer Depression Fatigue +1 more

UNKNOWN

The Use of Metformin in Early Breast Cancer Patients Pre-Surgery

NCT01302002

Breast Cancer

WITHDRAWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

11C-metformin uptake in breast cancer. Single center, single dose, open-label.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

11C-metformin

All participants allocated to the study will be included in this arm

Group Type EXPERIMENTAL

11C-metformin

Intervention Type RADIATION

400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

11C-metformin

400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* over 50 years
* C. mammae
* Tumor size: \> 10 mm in diameter
* Unilateral cancer
* WHO performance status 0-1

Exclusion Criteria

* Severe heart- or kidney failure
* Pregnant or breast feeding
* If the patient is found not eligible for participation in the study på principal investigator

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No